According to a multicenter randomized clinical trial in 2011, anti-vascular endothelial growth factor agents (VEGF) injection intravitreally was found to be efficient in treating ROP (3), and subsequent reports revealed that anti-VEGF treatment was less likely to cause ocular complications mentioned above, compared to laser photocoagulation (4, 5). Here, VEGFA is linked to retinopathy of prematurity.